CompletedPhase 1

Study of SGB-3908 in Healthy Subjects and Mildly Hypertensive Subjects

China40 participantsStarted 2024-07-31

Plain-language summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) effects of SGB-3908 in healthy subjects and mildly hypertensive subjects. The study will be a single ascending dose (SAD) phase.

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin higher than 1.5× upper limit of normal (ULN)
✕. Serum creatinine (Cr) higher than ULN
✕. Serum potassium higher than 5 mmol/L
✕. QT/QTc interval prolongation during screening (QTcF\>450 ms)

What they're measuring

Number of Participants with Adverse Events (AEs)

Timeframe: up to approximately 12 months

Trial details

NCT IDNCT06501586

SponsorSuzhou Sanegene Bio Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-04-07

View on ClinicalTrials.gov More Hypertension,Essential trials